A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells

Primary liver cancer is one of the most common cancer in the world with highest cancer mortality rate. The most common type of primary liver cancer is hepatocellular carcinoma (HCC). There are many risk factors for liver cancer and currently available treatments for HCC are largely inadequate. Gene...

Full description

Bibliographic Details
Main Authors: Nor Adzimah Johdi, Siti Nurmi Nasir, A. Rahman A. Jamal
Format: Article
Language:English
Published: Penerbit Universiti Kebangsaan Malaysia 2017
Online Access:http://journalarticle.ukm.my/11149/1/15%20Nor%20Adzimah%20Johdi.pdf
_version_ 1796931400362885120
author Nor Adzimah Johdi,
Siti Nurmi Nasir,
A. Rahman A. Jamal,
author_facet Nor Adzimah Johdi,
Siti Nurmi Nasir,
A. Rahman A. Jamal,
author_sort Nor Adzimah Johdi,
collection UKM
description Primary liver cancer is one of the most common cancer in the world with highest cancer mortality rate. The most common type of primary liver cancer is hepatocellular carcinoma (HCC). There are many risk factors for liver cancer and currently available treatments for HCC are largely inadequate. Gene mutation and dysfunction of p53 are common and is recognized as an important molecular event in hepatocarcinogenesis. Therefore, replacement of the aberrant p53 gene is an attractive approach in the treatment of HCC providing an alternative treatment for primary HCC. In this study, we assessed whether the transfection with wild-type p53 gene is able to restore the pro-apoptotic effects and evaluate the feasibility of gene therapy in fixing a faulty p53 molecule. We established a non-viral cationic lipid-based p53 gene delivery into two human HCC cell lines namely HLF and PLC/PRF/5 cells. Both cell lines have mutations in the p53 gene. We compared the results with the normal liver cell line, WRL68, that constitutively expresses the wild-type p53 gene. In this study, the introduction of wild-type p53 gene into HLF and PLC/PRF/5 cells resulted in an increased of p53 gene expression, protein expression and cells growth inhibition shown in MTS reduction cell viability assay, FITC-Annexin V and PI apoptosis assay, western blot and caspase activity assay. In summary, the study provides a promising therapeutic approach for p53 gene delivery into HCC patients. The p53 gene delivery can be instituted together with chemotherapy as a combination treatment to induce apoptosis.
first_indexed 2024-03-06T04:17:29Z
format Article
id ukm.eprints-11149
institution Universiti Kebangsaan Malaysia
language English
last_indexed 2024-03-06T04:17:29Z
publishDate 2017
publisher Penerbit Universiti Kebangsaan Malaysia
record_format dspace
spelling ukm.eprints-111492017-12-23T03:15:32Z http://journalarticle.ukm.my/11149/ A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells Nor Adzimah Johdi, Siti Nurmi Nasir, A. Rahman A. Jamal, Primary liver cancer is one of the most common cancer in the world with highest cancer mortality rate. The most common type of primary liver cancer is hepatocellular carcinoma (HCC). There are many risk factors for liver cancer and currently available treatments for HCC are largely inadequate. Gene mutation and dysfunction of p53 are common and is recognized as an important molecular event in hepatocarcinogenesis. Therefore, replacement of the aberrant p53 gene is an attractive approach in the treatment of HCC providing an alternative treatment for primary HCC. In this study, we assessed whether the transfection with wild-type p53 gene is able to restore the pro-apoptotic effects and evaluate the feasibility of gene therapy in fixing a faulty p53 molecule. We established a non-viral cationic lipid-based p53 gene delivery into two human HCC cell lines namely HLF and PLC/PRF/5 cells. Both cell lines have mutations in the p53 gene. We compared the results with the normal liver cell line, WRL68, that constitutively expresses the wild-type p53 gene. In this study, the introduction of wild-type p53 gene into HLF and PLC/PRF/5 cells resulted in an increased of p53 gene expression, protein expression and cells growth inhibition shown in MTS reduction cell viability assay, FITC-Annexin V and PI apoptosis assay, western blot and caspase activity assay. In summary, the study provides a promising therapeutic approach for p53 gene delivery into HCC patients. The p53 gene delivery can be instituted together with chemotherapy as a combination treatment to induce apoptosis. Penerbit Universiti Kebangsaan Malaysia 2017-08 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/11149/1/15%20Nor%20Adzimah%20Johdi.pdf Nor Adzimah Johdi, and Siti Nurmi Nasir, and A. Rahman A. Jamal, (2017) A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells. Sains Malaysiana, 46 (8). pp. 1289-1297. ISSN 0126-6039 http://www.ukm.my/jsm/malay_journals/jilid46bil8_2017/KandunganJilid46Bil8_2017.html
spellingShingle Nor Adzimah Johdi,
Siti Nurmi Nasir,
A. Rahman A. Jamal,
A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
title A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
title_full A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
title_fullStr A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
title_full_unstemmed A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
title_short A gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
title_sort gain of function p53 gene mutant promotes growth suppression in human liver cancer cells
url http://journalarticle.ukm.my/11149/1/15%20Nor%20Adzimah%20Johdi.pdf
work_keys_str_mv AT noradzimahjohdi againoffunctionp53genemutantpromotesgrowthsuppressioninhumanlivercancercells
AT sitinurminasir againoffunctionp53genemutantpromotesgrowthsuppressioninhumanlivercancercells
AT arahmanajamal againoffunctionp53genemutantpromotesgrowthsuppressioninhumanlivercancercells
AT noradzimahjohdi gainoffunctionp53genemutantpromotesgrowthsuppressioninhumanlivercancercells
AT sitinurminasir gainoffunctionp53genemutantpromotesgrowthsuppressioninhumanlivercancercells
AT arahmanajamal gainoffunctionp53genemutantpromotesgrowthsuppressioninhumanlivercancercells